Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Accumulated Expenses for 2 consecutive years, with $28009.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 11.36% to $28009.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28009.0 through Dec 2025, down 11.36% year-over-year, with the annual reading at $35756.0 for FY2025, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $28009.0 at Neuphoria Therapeutics, down from $32698.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $35756.0 in Q2 2025, with the low at $28009.0 in Q4 2025.